% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Beguin:866736,
author = {Beguin, Estelle and Gray, Michael D. and Logan, Keiran A.
and Nesbitt, Heather and Sheng, Yingjie and Kamila, Sukanta
and Barnsley, Lester C. and Bau, Luca and McHale, Anthony P.
and Callan, John F. and Stride, Eleanor},
title = {{M}agnetic microbubble mediated chemo-sonodynamic therapy
using a combined magnetic-acoustic device},
journal = {Journal of controlled release},
volume = {317},
issn = {0168-3659},
address = {New York, NY [u.a.]},
publisher = {Elsevier},
reportid = {FZJ-2019-05805},
pages = {23 - 33},
year = {2020},
note = {© 2019 The Authors. Published by Elsevier B.V. This is an
open access article under the CC BY license
(http://creativecommons.org/licenses/BY/4.0/).},
abstract = {Recent pre-clinical studies have demonstrated the potential
of combining chemotherapy and sonodynamic therapy for the
treatment of pancreatic cancer. Oxygen-loaded magnetic
microbubbles have been explored as a targeted delivery
vehicle for this application. Despite preliminary positive
results, a previous study identified a significant practical
challenge regarding the co-alignment of the magnetic and
ultrasound fields. The aim of this study was to determine
whether this challenge could be addressed through the use of
a magnetic-acoustic device (MAD) combining a magnetic array
and ultrasound transducer in a single unit, to
simultaneously concentrate and activate the microbubbles at
the target site. in vitro experiments were performed in
tissue phantoms and followed by in vivo treatment of
xenograft pancreatic cancer (BxPC-3) tumours in a murine
model. In vitro, a 1.4-fold (p < .01) increase in the
deposition of a model therapeutic payload within the phantom
was achieved using the MAD compared to separate magnetic and
ultrasound devices. In vivo, tumours treated with the MAD
had a $9\%$ smaller mean volume 8 days after treatment,
while tumours treated with separate devices or microbubbles
alone were respectively $45\%$ and $112\%$ larger. This
substantial and sustained decrease in tumour volume suggests
that the proposed drug delivery approach has the potential
to be an effective neoadjuvant therapy for pancreatic cancer
patients.},
cin = {JCNS-FRM-II / JCNS-1 / MLZ},
ddc = {610},
cid = {I:(DE-Juel1)JCNS-FRM-II-20110218 /
I:(DE-Juel1)JCNS-1-20110106 / I:(DE-588b)4597118-3},
pnm = {6G4 - Jülich Centre for Neutron Research (JCNS) (POF3-623)
/ 6G15 - FRM II / MLZ (POF3-6G15)},
pid = {G:(DE-HGF)POF3-6G4 / G:(DE-HGF)POF3-6G15},
experiment = {EXP:(DE-MLZ)NOSPEC-20140101},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31733295},
UT = {WOS:000512730700002},
doi = {10.1016/j.jconrel.2019.11.013},
url = {https://juser.fz-juelich.de/record/866736},
}